Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Recent advances in recombinant protein-based malaria vaccines. Vaccine (2015) 0.91

Designing malaria vaccines to circumvent antigen variability. Vaccine (2015) 0.83

Progress and prospects for blood-stage malaria vaccines. Expert Rev Vaccines (2016) 0.82

Immunization with the Malaria Diversity-Covering Blood-Stage Vaccine Candidate Plasmodium falciparum Apical Membrane Antigen 1 DiCo in Complex with Its Natural Ligand PfRon2 Does Not Improve the In Vitro Efficacy. Front Immunol (2017) 0.75

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28

Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun (2001) 4.51

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect Immun (2002) 4.02

Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51

A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20

The disulfide bond structure of Plasmodium apical membrane antigen-1. J Biol Chem (1996) 3.15

Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics (2001) 2.89

Phage display for selection of novel binding peptides. Methods Enzymol (2000) 2.78

Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol (2008) 2.63

Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A (2005) 2.50

Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem (1998) 2.44

Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22

Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A (2007) 2.15

The future for blood-stage vaccines against malaria. Immunol Cell Biol (2009) 2.04

Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02

Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. J Clin Invest (2008) 1.96

Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95

The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun (2006) 1.85

Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics (2003) 1.82

A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun (2008) 1.73

Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A (2008) 1.69

Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem (2006) 1.47

Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One (2009) 1.45

Structural and functional insights into the malaria parasite moving junction complex. PLoS Pathog (2012) 1.44

Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum. PLoS One (2009) 1.43

Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog (2007) 1.42

Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng (2001) 1.35

A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine (2009) 1.33

Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog (2013) 1.30

Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis (2012) 1.30

Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J (2010) 1.27

Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure (2007) 1.26

Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One (2012) 1.23

Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. Infect Immun (2010) 1.20

In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun (2007) 1.15

Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccin (2010) 1.11

Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1. Infect Immun (2013) 1.05

Alanine mutagenesis of the primary antigenic escape residue cluster, c1, of apical membrane antigen 1. Infect Immun (2009) 0.98

Mixed allele malaria vaccines: host protection and within-host selection. Vaccine (2008) 0.94

Sequence diversity and natural selection at domain I of the apical membrane antigen 1 among Indian Plasmodium falciparum populations. Malar J (2007) 0.93

Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Med (2013) 0.91

Antibodies to polymorphic invasion-inhibitory and non-Inhibitory epitopes of Plasmodium falciparum apical membrane antigen 1 in human malaria. PLoS One (2013) 0.88

The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci Rep (2016) 0.75